Trial Profile

A Phase 1, Open-label, Multicenter, First-in-Human Trial of DS3610a in Participants With Advanced Solid Tumor

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DS 3610a (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Daiichi Sankyo Company

Most Recent Events

10 Nov 2025 According to a Daiichi Sankyo media release, trial is expected to enroll patients across multiple sites globally, including Asia, Europe and North America.
10 Nov 2025 Status changed to recruiting.
10 Nov 2025 According to a Daiichi Sankyo media release, first patient has been dosed in a first-inhuman phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com